甲状腺乳头状癌组织中CDKN2A/p14^(ARF)蛋白表达及其临床意义  

The expression of CDKN2A/p14^(ARF) protein and its′ clinical significance in papillary thyroid carcinoma

作　　者：五且昆.吐尔逊 林晨[2] 夏米西努尔.伊力克 

机构地区：[1]新疆医科大学基础医学院生物学教研室,新疆乌鲁木齐830011 [2]新疆医科大学基础医学院病理学教研室,新疆乌鲁木齐830011

出　　处：《新疆医科大学学报》2011年第5期466-469,共4页Journal of Xinjiang Medical University

基　　金：国家自然科学基金(30860275)

摘　　要：目的通过检测CDKN2A/p14ARF蛋白在甲状腺乳头状癌组织中的表达,探讨并分析CDKN2A/p14ARF在甲状腺乳头状癌发生发展中的作用和在癌旁正常甲状腺组织与甲状腺乳头状癌之间表达的差异。方法采用免疫组织化学方法(SP法)检测甲状腺乳头状癌和癌旁正常甲状腺组织中CDKN2A/p14ARF蛋白的表达情况,并进行统计学分析。结果 CDKN2A/p14ARF在甲状腺乳头状癌组织中表达阳性率87.8%(36/41),其中阳性程度在(++)以上者20例,占48.8%(20/41)。癌旁正常甲状腺组织阳性率为75%(15/20),甲状腺乳头状癌和癌旁正常甲状腺组织之间差异有统计学意义(P<0.05)。在甲状腺乳头状癌中CDKN2A/p14ARF蛋白表达与患者性别、年龄之间的差异无统计学意义(P>0.05)。结论 CDKN2A/p14ARF在甲状腺乳头状癌中表达率极高,是甲状腺乳头状癌病理诊断中非常有价值的辅助诊断指标。Objective Throughout testing the immunohistochemic expression of CDKN2A/p14ARF in the papillary thyroid carcinoma tissue,to explore the protein function during the development of the papillary thyroid carcinoma.To analyze the different expressions between the para-tumor normal tissues and the papillary thyroid carcinoma.Methods Immunohistochemistry（S-P method） was esed to find out the expression of CDKN2A/p14ARF in the papillary thyroid carcinoma and para-tumor normal tissues.At the same time,the statistics way was used to analyze.Results CDKN2A/p14ARF positive rate was 87.8%（36/41）in the expression of the papillary thyroid carcinoma,20 cases reached a degree above（＋＋）,accounting for 48.8%（20/41）.The positive rate of para-tumor normal tissues was 75%（15/20）.Compared to the papillary thyroid carcinoma and para-tumor normal tissues of thyroid gland pathologically,the difference was higher（P0.05）.The expression of CDKN2A/p14ARF did not have obvious dependablity with the sex or age were not statistically significant（P0.05）.Conclusion CDKN2A/p14ARF have an extremely high expression rate in the papillary thyroid carcinoma,which is remarkably valuable assistant diagnostic points in the pathological diagnosis text.

关 键 词：甲状腺乳头状癌 CDKN2A/p14ARF 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤] R36[医药卫生—临床医学]